We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year increase of 5.6%. Revenues are expected to be $3.96 billion, up 2% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Teva Pharmaceutical Industries Ltd. metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenue- Other- Total' at $194.26 million. The estimate points to a change of -16.3% from the year-ago quarter.
Analysts expect 'Revenue- API sales to third parties' to come in at $159.44 million. The estimate suggests a change of -5.1% year over year.
It is projected by analysts that the 'Revenue- COPAXONE- Total' will reach $139.08 million. The estimate indicates a change of -17.7% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- International Markets' reaching $473.55 million. The estimate indicates a change of -1.8% from the prior-year quarter.
According to the collective judgment of analysts, 'Geographic Revenue- North America' should come in at $2.04 billion. The estimate indicates a year-over-year change of +1.8%.
The consensus among analysts is that 'Geographic Revenue- North America- COPAXONE' will reach $75.07 million. The estimate indicates a year-over-year change of -25.7%.
Analysts forecast 'Geographic Revenue- North America- BENDEKA / TREANDA' to reach $49.38 million. The estimate indicates a change of -34.2% from the prior-year quarter.
The consensus estimate for 'Geographic Revenue- North America- AUSTEDO' stands at $422.38 million. The estimate indicates a change of +22.8% from the prior-year quarter.
Analysts predict that the 'Geographic Revenue- North America- Anda' will reach $450.39 million. The estimate indicates a year-over-year change of +0.1%.
The combined assessment of analysts suggests that 'Geographic Revenue- Europe- COPAXONE' will likely reach $45.16 million. The estimate indicates a year-over-year change of -26%.
Based on the collective assessment of analysts, 'Geographic Revenue- Europe- Respiratory products' should arrive at $71.77 million. The estimate indicates a year-over-year change of -4.3%.
The collective assessment of analysts points to an estimated 'Geographic Revenue- International Markets- Generic products' of $403.85 million. The estimate indicates a year-over-year change of -1.7%.
Shares of Teva Pharmaceutical Industries Ltd. have experienced a change of +13% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TEVA is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year increase of 5.6%. Revenues are expected to be $3.96 billion, up 2% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Teva Pharmaceutical Industries Ltd. metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenue- Other- Total' at $194.26 million. The estimate points to a change of -16.3% from the year-ago quarter.
Analysts expect 'Revenue- API sales to third parties' to come in at $159.44 million. The estimate suggests a change of -5.1% year over year.
It is projected by analysts that the 'Revenue- COPAXONE- Total' will reach $139.08 million. The estimate indicates a change of -17.7% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- International Markets' reaching $473.55 million. The estimate indicates a change of -1.8% from the prior-year quarter.
According to the collective judgment of analysts, 'Geographic Revenue- North America' should come in at $2.04 billion. The estimate indicates a year-over-year change of +1.8%.
The consensus among analysts is that 'Geographic Revenue- North America- COPAXONE' will reach $75.07 million. The estimate indicates a year-over-year change of -25.7%.
Analysts forecast 'Geographic Revenue- North America- BENDEKA / TREANDA' to reach $49.38 million. The estimate indicates a change of -34.2% from the prior-year quarter.
The consensus estimate for 'Geographic Revenue- North America- AUSTEDO' stands at $422.38 million. The estimate indicates a change of +22.8% from the prior-year quarter.
Analysts predict that the 'Geographic Revenue- North America- Anda' will reach $450.39 million. The estimate indicates a year-over-year change of +0.1%.
The combined assessment of analysts suggests that 'Geographic Revenue- Europe- COPAXONE' will likely reach $45.16 million. The estimate indicates a year-over-year change of -26%.
Based on the collective assessment of analysts, 'Geographic Revenue- Europe- Respiratory products' should arrive at $71.77 million. The estimate indicates a year-over-year change of -4.3%.
The collective assessment of analysts points to an estimated 'Geographic Revenue- International Markets- Generic products' of $403.85 million. The estimate indicates a year-over-year change of -1.7%.
View all Key Company Metrics for Teva Pharmaceutical Industries Ltd. here>>>
Shares of Teva Pharmaceutical Industries Ltd. have experienced a change of +13% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TEVA is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>